SK14512003A3 - Spôsob liečenia demencie a neurodegeneratívnych chorôb strednými dávkami LHRH antagonistov - Google Patents
Spôsob liečenia demencie a neurodegeneratívnych chorôb strednými dávkami LHRH antagonistov Download PDFInfo
- Publication number
- SK14512003A3 SK14512003A3 SK1451-2003A SK14512003A SK14512003A3 SK 14512003 A3 SK14512003 A3 SK 14512003A3 SK 14512003 A SK14512003 A SK 14512003A SK 14512003 A3 SK14512003 A3 SK 14512003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- lhrh
- use according
- antagonist
- methyl
- treatment
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims abstract description 15
- 206010012289 Dementia Diseases 0.000 title claims abstract description 10
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 8
- 239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 108700008462 cetrorelix Proteins 0.000 claims abstract description 4
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims abstract description 4
- 229960003230 cetrorelix Drugs 0.000 claims abstract description 4
- -1 2,5-Dimethyl-furan-3-yl Chemical group 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 9
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- QGGCIYXVQZHCKK-UHFFFAOYSA-N 3-[[[2-[1-(3,5-difluorophenyl)-3-(2-methoxyphenyl)-1,3-dioxopropan-2-ylidene]-1,3-dihydrobenzimidazol-5-yl]amino]methyl]benzonitrile Chemical compound COC1=CC=CC=C1C(=O)C(C(=O)C=1C=C(F)C=C(F)C=1)=C1NC2=CC(NCC=3C=C(C=CC=3)C#N)=CC=C2N1 QGGCIYXVQZHCKK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 108010023617 abarelix Proteins 0.000 claims description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 2
- 229960002184 abarelix Drugs 0.000 claims description 2
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical group C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 2
- 108010083551 iturelix Proteins 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims 5
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims 5
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims 5
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 5
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- 108700012941 GNRH1 Proteins 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 159000000021 acetate salts Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK14512003A3 true SK14512003A3 (sk) | 2004-08-03 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1451-2003A SK14512003A3 (sk) | 2001-04-30 | 2002-04-27 | Spôsob liečenia demencie a neurodegeneratívnych chorôb strednými dávkami LHRH antagonistov |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (https=) |
| EP (1) | EP1392348B1 (https=) |
| JP (1) | JP2004529207A (https=) |
| KR (1) | KR20040000446A (https=) |
| CN (1) | CN1317030C (https=) |
| AT (1) | ATE400287T1 (https=) |
| AU (1) | AU2002310788B2 (https=) |
| BG (1) | BG108339A (https=) |
| BR (1) | BR0209290A (https=) |
| CA (1) | CA2444876A1 (https=) |
| CZ (1) | CZ20033167A3 (https=) |
| DE (1) | DE60227507D1 (https=) |
| DK (1) | DK1392348T3 (https=) |
| ES (1) | ES2307760T3 (https=) |
| HU (1) | HUP0400067A2 (https=) |
| IL (1) | IL156777A0 (https=) |
| MX (1) | MXPA03008666A (https=) |
| NO (1) | NO20034322L (https=) |
| NZ (1) | NZ544417A (https=) |
| PL (1) | PL362319A1 (https=) |
| PT (1) | PT1392348E (https=) |
| RU (1) | RU2319501C2 (https=) |
| SI (1) | SI1392348T1 (https=) |
| SK (1) | SK14512003A3 (https=) |
| UA (1) | UA80679C2 (https=) |
| WO (1) | WO2002102401A1 (https=) |
| ZA (1) | ZA200305326B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US6960591B2 (en) * | 2000-07-05 | 2005-11-01 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivative |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| US7709519B2 (en) * | 2004-06-04 | 2010-05-04 | Astellas Pharma Inc. | Benzimidazolylidene propane-1,3 dione derivative or salt thereof |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| US20060142186A1 (en) * | 2004-12-23 | 2006-06-29 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease |
| EP1864976B1 (en) | 2005-03-31 | 2012-10-10 | Astellas Pharma Inc. | Propane-1,3-dion derivative or salt thereof |
| CN101573352A (zh) * | 2006-10-21 | 2009-11-04 | 艾博特股份有限两合公司 | 杂环化合物和其作为糖原合酶激酶3抑制剂的用途 |
| KR20100056508A (ko) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 폐렴 연쇄상 구균 감염의 치료를 위한 ｂｆｇｆ １－２４ 및 임의의 （ａｒｇ ８）바소프레신의 용도 |
| WO2009033730A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratoires Ag | Peptide gxgrgdspca as a therapeutic agent |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| EP2307040B1 (en) * | 2008-05-29 | 2015-09-09 | Isr Immune System Regulation Ab | Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids |
| MX336726B (es) | 2010-09-27 | 2016-01-27 | Abbott Gmbh & Co Kg | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3. |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| AU710926B2 (en) | 1996-05-20 | 1999-09-30 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| CA2372044A1 (en) | 1999-05-14 | 2000-11-23 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| MXPA02003614A (es) * | 1999-10-15 | 2002-10-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos.. |
| US20030134863A1 (en) | 2000-04-13 | 2003-07-17 | Shuichi Furuya | Preventives/remedies for alzheimer's disease |
| US6960591B2 (en) * | 2000-07-05 | 2005-11-01 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivative |
-
2002
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322L/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20034322D0 (no) | 2003-09-26 |
| US20020177556A1 (en) | 2002-11-28 |
| UA80679C2 (en) | 2007-10-25 |
| MXPA03008666A (es) | 2004-10-15 |
| CN1575185A (zh) | 2005-02-02 |
| HK1072000A1 (en) | 2005-08-12 |
| ES2307760T3 (es) | 2008-12-01 |
| BG108339A (bg) | 2004-11-30 |
| BR0209290A (pt) | 2004-07-13 |
| EP1392348A1 (en) | 2004-03-03 |
| HUP0400067A2 (hu) | 2004-04-28 |
| CZ20033167A3 (cs) | 2004-08-18 |
| JP2004529207A (ja) | 2004-09-24 |
| IL156777A0 (en) | 2004-02-08 |
| PT1392348E (pt) | 2008-09-09 |
| ATE400287T1 (de) | 2008-07-15 |
| CN1317030C (zh) | 2007-05-23 |
| NZ544417A (en) | 2008-03-28 |
| WO2002102401A1 (en) | 2002-12-27 |
| DE60227507D1 (de) | 2008-08-21 |
| CA2444876A1 (en) | 2002-12-27 |
| PL362319A1 (en) | 2004-10-18 |
| RU2319501C2 (ru) | 2008-03-20 |
| EP1392348B1 (en) | 2008-07-09 |
| ZA200305326B (en) | 2003-07-30 |
| NO20034322L (no) | 2003-09-26 |
| AU2002310788B2 (en) | 2007-04-05 |
| KR20040000446A (ko) | 2004-01-03 |
| RU2003134949A (ru) | 2005-02-10 |
| SI1392348T1 (sl) | 2008-12-31 |
| US7288517B2 (en) | 2007-10-30 |
| DK1392348T3 (da) | 2008-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK14512003A3 (sk) | Spôsob liečenia demencie a neurodegeneratívnych chorôb strednými dávkami LHRH antagonistov | |
| JP2006502969A (ja) | 内因性性腺刺激ホルモン産生の増強 | |
| AU2002310788A1 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| EA020193B1 (ru) | Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh) | |
| KR20070116181A (ko) | 보존 제약 제형 | |
| EP3566695B1 (en) | Treatment of coccidiosis with intramuscular triazine compositions | |
| EP1171124B2 (en) | Anthelmintic compositions | |
| DE69927705T2 (de) | Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen-gonadenachse | |
| RU2002115406A (ru) | Соединение, обладающее свойствами высвобождения гормона роста | |
| KR19990023021A (ko) | 신규한 의약 용도 | |
| Cagnoli et al. | Relation between hydrocarbon exposure and the nephrotic syndrome | |
| WO2001012204A2 (en) | Xanthine oxidase inhibitor containing compositions for the treatment of acetaminophen intoxication | |
| HUP9900227A2 (hu) | AII-receptor antagonisták új gyógyszerészeti felhasználása | |
| US6448280B1 (en) | Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| KR20030051828A (ko) | 에스트로겐 의존성 질환의 병용 치료법 | |
| HK1072000B (en) | Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists | |
| CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
| US20040157772A1 (en) | Use of a gatran for the manufacture of a medicament of the treatment of pulmonary fibrosis | |
| JPH0296521A (ja) | 免疫性疾患治療剤 | |
| SK285257B6 (sk) | Imunologicky účinné prípravky z extraktu imela | |
| JPH04506969A (ja) | 成人男性における不妊症又は生殖能力低下の治療方法および該方法のための製剤の使用 | |
| AU2002305989A1 (en) | The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis |